Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) (ConCoVid-19)
Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19
Sponsor: Erasmus Medical Center
Terminated
new insights into COVID19 pathogenesis
This PHASE2/PHASE3 trial investigates COVID-19 and is currently terminated or withdrawn. Erasmus Medical Center leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
Status: Active Not Recruiting → Terminated
-
Jan 2022 — May 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2020 — Dec 2020 [monthly]
Recruiting PHASE2_PHASE3
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
- Prothya Biosolutions
For direct contact, visit the study record on ClinicalTrials.gov .